Corruption Risk: Responding to Critical Issues in the Pharmaceutical Industry

Posted 01 November 2010 | By

As regulators and law enforcement officials in the US and abroad shine brighter spotlights on the pharmaceutical industry, it is more important than ever for life sciences companies to have programs to evaluate, mitigate and monitor corruption risk. A robust anti-corruption compliance program provides a critical "rule book" for life sciences companies conducting business in today's global economy.

Categories:

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe